Gerard Marek
Gerard Marek
Gilgamesh Pharmaceuticals
Verified email at gilgameshpharmaceutical.com
Title
Cited by
Cited by
Year
Serotonin model of schizophrenia: emerging role of glutamate mechanisms
GK Aghajanian, GJ Marek
Brain research reviews 31 (2-3), 302-312, 2000
5762000
Glutamate and GABA systems as targets for novel antidepressant and mood-stabilizing treatments
JH Krystal, G Sanacora, H Blumberg, A Anand, DS Charney, G Marek, ...
Molecular psychiatry 7 (1), S71-S80, 2002
5592002
Serotonin induces excitatory postsynaptic potentials in apical dendrites of neocortical pyramidal cells
GK Aghajanian, GJ Marek
Neuropharmacology 36 (4-5), 589-599, 1997
5181997
5-HT2A receptor-mediated regulation of brain-derived neurotrophic factor mRNA in the hippocampus and the neocortex
VA Vaidya, GJ Marek, GK Aghajanian, RS Duman
Journal of Neuroscience 17 (8), 2785-2795, 1997
4821997
Serotonin and hallucinogens
GK Aghajanian, GJ Marek
Neuropsychopharmacology 21 (2), 16S-23S, 1999
4681999
Serotonin, via 5-HT2A receptors, increases EPSCs in layer V pyramidal cells of prefrontal cortex by an asynchronous mode of glutamate release
GK Aghajanian, GJ Marek
Brain research 825 (1-2), 161-171, 1999
3681999
Physiological antagonism between 5-hydroxytryptamine2A and group II metabotropic glutamate receptors in prefrontal cortex
GJ Marek, RA Wright, DD Schoepp, JA Monn, GK Aghajanian
Journal of Pharmacology and Experimental Therapeutics 292 (1), 76-87, 2000
3012000
Synergistic action of 5-HT 2A antagonists and selective serotonin reuptake inhibitors in neuropsychiatric disorders
GJ Marek, LL Carpenter, CJ McDougle, LH Price
Neuropsychopharmacology 28 (2), 402-412, 2003
2892003
5-HT2A receptor or α1-adrenoceptor activation induces excitatory postsynaptic currents in layer V pyramidal cells of the medial prefrontal cortex
GJ Marek, GK Aghajanian
European journal of pharmacology 367 (2-3), 197-206, 1999
2341999
Metabotropic glutamate receptors in the control of mood disorders
JM Witkin, GJ Marek, BG Johnson, DD Schoepp
CNS & Neurological Disorders-Drug Targets (Formerly Current Drug Targets-CNS …, 2007
1762007
Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain?
GJ Marek, B Behl, AY Bespalov, G Gross, Y Lee, H Schoemaker
Molecular pharmacology 77 (3), 317-326, 2010
1732010
LSD and the phenethylamine hallucinogen DOI are potent partial agonists at 5-HT2A receptors on interneurons in rat piriform cortex.
GJ Marek, GK Aghajanian
Journal of Pharmacology and Experimental Therapeutics 278 (3), 1373-1382, 1996
1661996
A major role for thalamocortical afferents in serotonergic hallucinogen receptor function in the rat neocortex
GJ Marek, RA Wright, JC Gewirtz, DD Schoepp
Neuroscience 105 (2), 379-392, 2001
1652001
Dopamine uptake inhibitors block long-term neurotoxic effects of methamphetamine upon dopaminergic neurons
GJ Marek, G Vosmer, LS Seiden
Brain research 513 (2), 274-279, 1990
1611990
Behavioral evidence for interactions between a hallucinogenic drug and group II metabotropic glutamate receptors
JC Gewirtz, GJ Marek
Neuropsychopharmacology 23 (5), 569-576, 2000
1582000
Essential role of the fosB gene in molecular, cellular, and behavioral actions of chronic electroconvulsive seizures
N Hiroi, GJ Marek, JR Brown, H Ye, F Saudou, VA Vaidya, RS Duman, ...
Journal of Neuroscience 18 (17), 6952-6962, 1998
1571998
Neurotoxicity in dopamine and 5‐hydroxytryptamine terminal fields: a regional analysis in nigrostriatal and mesolimbic projections
LS Seiden, DL Commins, G Vosmer, K Axt, G Marek
Annals of the New York Academy of Sciences 537 (1), 161-172, 1988
1391988
A comparison of trazodone and fluoxetine: implications for a serotonergic mechanis of antidepressant action
GJ Marek, CJ McDougle, LH Price, LS Seiden
Psychopharmacology 109 (1), 2-11, 1992
1321992
The selective 5-HT 2A receptor antagonist M100907 enhances antidepressant-like behavioral effects of the SSRI fluoxetine
GJ Marek, R Martin-Ruiz, A Abo, F Artigas
Neuropsychopharmacology 30 (12), 2205-2215, 2005
1222005
Preclinical pharmacology of mGlu2/3 receptor agonists: novel agents for schizophrenia?
DD Schoepp, GJ Marek
Current Drug Targets-CNS & Neurological Disorders 1 (2), 215-225, 2002
1212002
The system can't perform the operation now. Try again later.
Articles 1–20